Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
about
Intravenous laser blood irradiation increases efficacy of etanercept in selected subtypes of juvenile idiopathic arthritis: an innovative clinical research approach.Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid populationDrug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis.Clinical use of biologics in vasculitis syndromes.Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting.Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort StudyDose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.The Risk of Glioblastoma with TNF Inhibitors.Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan.Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
P2860
Q31130038-283A3974-6D15-4B44-B408-CA2C75B962B5Q34211985-F02985AB-5839-4AFA-8844-49170E7D0914Q36274355-E302E4CA-FC41-464F-9FB6-41D230E5A159Q36358081-9D86D848-E638-4745-910C-FFC66944E954Q36923598-8184A233-D7DD-4331-B72A-0519A790A595Q37143744-4BA02CCB-FD36-4EB2-A166-724D93C3D5BFQ37452967-D90D4E35-C5D8-4E39-BC92-FE5201CEA092Q38338700-B30AE0DA-0E15-49CA-8F42-522BC0D96BECQ38822920-7F43EC55-E4D5-4E8A-A8A6-8BDCE0545594Q39956333-B2C5E88E-E80B-4C89-863E-F4875BA8E41DQ45972851-8AE138F9-CDD8-4DA6-B9CA-12EEF3F3CA2AQ51136025-AFCA41FC-DA32-4C58-BA8D-FF5CCD7B9BBCQ53307697-4BE85C5A-6635-46D9-9A77-0F21E7953D0C
P2860
Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Annual costs of tumor necrosis ...... pulation in the United States.
@ast
Annual costs of tumor necrosis ...... pulation in the United States.
@en
Annual costs of tumor necrosis ...... pulation in the United States.
@nl
type
label
Annual costs of tumor necrosis ...... pulation in the United States.
@ast
Annual costs of tumor necrosis ...... pulation in the United States.
@en
Annual costs of tumor necrosis ...... pulation in the United States.
@nl
prefLabel
Annual costs of tumor necrosis ...... pulation in the United States.
@ast
Annual costs of tumor necrosis ...... pulation in the United States.
@en
Annual costs of tumor necrosis ...... pulation in the United States.
@nl
P2093
P1476
Annual costs of tumor necrosis ...... pulation in the United States.
@en
P2093
David J Harrison
Kathleen M Fox
Seth Goodman
Shravanthi R Gandra
Vernon F Schabert
P304
P356
10.3111/13696998.2011.644645
P407
P577
2011-12-08T00:00:00Z